Literature DB >> 2879105

Clinical significance of tamoxifen withdrawal response.

P A Canney, T Griffiths, T N Latief, T J Priestman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2879105     DOI： 10.1016/s0140-6736(87)90717-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  20 in total

Review 1.  The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.

Authors:  Donald P McDonnell; Suzanne E Wardell
Journal:  Curr Opin Pharmacol       Date:  2010-12       Impact factor: 5.547

2.  Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

Authors:  Xiaonan Hou; Fei Huang; Luciana F Macedo; Sean C Harrington; Karen A Reeves; Ann Greer; Friedrich Graf Finckenstein; Angela Brodie; Marco M Gottardis; Joan M Carboni; Paul Haluska
Journal:  Cancer Res       Date:  2011-10-31       Impact factor: 12.701

3.  Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

Authors:  V Craig Jordan; Ramona Curpan; Philipp Y Maximov
Journal:  J Natl Cancer Inst       Date:  2015-04-02       Impact factor: 13.506

4.  A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}.

Authors:  Nicole M Kretzer; Milu T Cherian; Chengjian Mao; Irene O Aninye; Philip D Reynolds; Rachel Schiff; Paul J Hergenrother; Steven K Nordeen; Elizabeth M Wilson; David J Shapiro
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

Review 5.  Antiestrogens--tamoxifen, SERMs and beyond.

Authors:  K Dhingra
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

6.  Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.

Authors:  Suzanne E Wardell; Erik R Nelson; Christina A Chao; Donald P McDonnell
Journal:  Clin Cancer Res       Date:  2013-03-27       Impact factor: 12.531

Review 7.  Endocrine therapy for advanced breast cancer: a review.

Authors:  H B Muss
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

8.  Tamoxifen-stimulated growth of breast cancer due to p21 loss.

Authors:  Abde M Abukhdeir; Michele I Vitolo; Pedram Argani; Angelo M De Marzo; Bedri Karakas; Hiroyuki Konishi; John P Gustin; Josh Lauring; Joseph P Garay; Courtney Pendleton; Yuko Konishi; Brian G Blair; Keith Brenner; Elizabeth Garrett-Mayer; Hetty Carraway; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-27       Impact factor: 11.205

Review 9.  William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy.

Authors:  D M Wolf; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 10.  P21 and p27: roles in carcinogenesis and drug resistance.

Authors:  Abde M Abukhdeir; Ben Ho Park
Journal:  Expert Rev Mol Med       Date:  2008-07-01       Impact factor: 5.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.